• Brian Currey
      400 South Hope Street
      Los Angeles, CA, 90071
      Phone: +1-213-430-6685
      Fax: +1-213-430-6407
  • Margaret Ikeya
      2765 Sand Hill Road
      Menlo Park, CA, 94025
      Phone: +1-650-473-2645
      Fax: +1-650-473-2601
  • John Kappos
      610 Newport Center Drive, 17th Floor
      Newport Beach, CA, 92660
      Phone: +1-949-823-6954
      Fax: +1-949-823-6994
  • Warren Lazarow
      2765 Sand Hill Road
      Menlo Park, CA, 94025
      Phone: +1-650-473-2637
      Fax: +1-650-473-2601
  • David Murphy
      610 Newport Center Drive, 17th Floor
      Newport Beach, CA, 92660
      Phone: +1-949-823-6960
      Fax: +1-949-823-6994
  • Sam Zucker
      2765 Sand Hill Road
      Menlo Park, CA, 94025
      Phone: +1-650-473-2638
      Fax: +1-650-473-2601
LAWYERS

  • Affymetrix, Inc.
    Ajinomoto Co., Inc.
    Amylin Pharmaceuticals, Inc.
    Cell Genesys
    Celula, Inc.
    Clontech Laboratories, Inc.
    Cogentus Pharmaceuticals Inc.
    Insite Vision
    Johnson & Johnson
    Merck & Co., Inc.
    Nanogen, Inc.
    Nektar Therapeutics
    New Leaf Venture Partners
    Novartis Vaccines and Diagnostics
    SentreHeart, Inc.
    Sirna Therapeutics
    Sprout Group
    Transcept Pharmaceuticals, Inc.
    Vicuron Pharmaceuticals, Inc.
    WuXi Pharmatech Co., Ltd.

Life Sciences

Life sciences are inherently intricate and transformative pursuits.  Success requires a tremendous commitment to constant innovation and improvement, and an ability to see the bigger picture.  Effective legal counsel must share these traits.

O’Melveny’s Life Sciences Practice is dedicated to providing practical, results-oriented counsel to participants in the increasingly competitive global life sciences industry.  Our clients span the full spectrum of life sciences market players, from IP-intensive startups to heavyweight private equity consortiums to billion-dollar publicly listed companies.  And our work for them reflects our unique commitment to operating at the cutting edge between pioneering science and successful commerce.

With lawyers in key life sciences communities in the United States, Europe, and Asia, O’Melveny combines diverse legal proficiency with deep industry knowledge to provide clients with the full suite of relevant services on a global, and local, basis.  Our rare blend of multi-disciplinary experience in the life sciences sector includes unrivaled depth of experience in cross-border transactions, mergers and acquisitions; uncompromising excellence in corporate finance, restructuring and private and public offerings; and nationally recognized skill in handling pharmaceutical, products liability and intellectual property litigation.  From the creation, acquisition and transfer of business interests and technology, to the enforcement and defense of vital intellectual property assets, our clients depend on us to provide strategic advice and innovative, business-savvy solutions to the complex issues they face.  Whether the undertaking is the billion-dollar sale of Nobel Prize-winning RNAi technology, an US$11 billion private equity club deal, a NYSE listing for China’s largest medical device manufacturer, or a bet-the-company pharmaceutical mass tort, class action or patent infringement case, O’Melveny’s Life Sciences Practice offers integrated delivery of services on a global scope to serve the companies that will shape life — and living — in the years to come.

Key Facts

  • Our life sciences lawyers are recognized for their leadership by such national and international publications as Chambers and Partners, The Legal 500, Forbes, and the San Francisco Daily Journal.
  • Many of our lawyers hold advanced scientific degrees or have worked in-house — permitting us to offer practical counseling backed by real world experience.
  • Our ability to navigate complex issues at the intersection of seemingly disparate locations and business sectors makes us the lawyers to see for the most ambitious global and cross-border transactions, as with our representation of WuXi PharmaTech (Cayman) Inc., the leading China-based pharmaceutical and biotechnology research and development outsourcing company, in its US$212 million initial public offering on the New York Stock Exchange.
  • We appreciate the high-risk environment that life sciences companies face.  With decades of experience litigating high-stakes matters, including multi-venued, high-profile, pharmaceutical, products liability, and patent litigations, we have the insight needed to provide solid strategic advice to clients on the verge of acquiring new technology, or launching a new product -- placing them ahead of the curve on risk assessment, management and avoidance.
  • Indeed, O’Melveny’s compelling mix of industry experience, intellectual property strength, and first-class Asian and European resources offers life sciences clients a competitive edge in the dynamic and ever-changing life sciences landscape -- and we are proud of our long track record of providing integrated, comprehensive, and coordinated representation on the most complex and high-profile biotech and life sciences matters.
    • Our work on a recent US$1.1 billion acquisition of an RNA interference technology company, for example, involved lawyers from four of our offices collaborating seamlessly on antitrust, tax, intellectual property, and labor law issues.
    • In December 2006, we represented venture capital investor The Sprout Group in the US$100 million financing of Kalypsys, named the largest private biotech financing of 2006 by The Deal.  One month later, we represented a consortium of venture capital investors in the largest private biotech financing in history: the US$670 million “minnow-swallows-whale” acquisition financing of Ikaria.
    • Over the past 30 years, we have defended hundreds of consumer class actions in 45 states and regularly serve as lead counsel to large pharmaceutical and medical device companies in high-profile mass tort proceedings, class actions, and government enforcement actions, including wrongful death and personal injury cases.
    • We also have extensive experience litigating multi-faceted intellectual property and technology disputes in forums around the nation. Our work for OrthoClear is but one example in which we successfully handled related matters simultaneously pending in multiple state and federal courts and the International Trade Commission.

Industry Reach

We represent clients in a wide range of industries, including:

  • Biotechnology 
  • Drug discovery 
  • Genomics 
  • Medical devices 
  • Nanotechnology 
  • Pharmaceuticals


B. Braun (Central Admixture Pharmacy Services, Inc.) Fabrus Vicuron Pharmaceuticals, Inc. OrthoClear, Inc. Sirna Therapeutics New Leaf Venture Partners Affymetrix, Inc Clontech Laboratories, Inc.